Nanohale AG (FYB) | Finanzwire

BRIEF

published on 07/30/2024 at 06:55, 3 months 22 days ago

Formycon Begins Phase III Clinical Trial for Keytruda® Biosimilar FYB206

Clinical Trials Biosimilar Formycon FYB206 Keytruda
PRESS RELEASE

published on 07/30/2024 at 06:50, 3 months 22 days ago

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda

Formycon AG NSCLC Phase III Trial FYB206 Keytruda Biosimilar
BRIEF

published on 07/26/2024 at 12:05, 3 months 26 days ago

Formycon and Fresenius Kabi Receive Positive CHMP Opinion for FYB202 (Ustekinumab)

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
PRESS RELEASE

published on 07/26/2024 at 12:00, 3 months 26 days ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 3 months 26 days ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 3 months 26 days ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA
BRIEF

published on 07/01/2024 at 06:55, 4 months 20 days ago

Formycon Receives FDA Approval for Aflibercept Biosimilar

FDA Approval Biosimilar Formycon Retinal Diseases Ophthalmic Therapies
PRESS RELEASE

published on 07/01/2024 at 06:50, 4 months 20 days ago

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases.

FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF

published on 06/28/2024 at 23:55, 4 months 22 days ago

FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases

FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
PRESS RELEASE

published on 06/28/2024 at 23:50, 4 months 22 days ago

EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases

FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration

Published on 11/21/2024 at 16:30, 38 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 7 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 8 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 1 hour 8 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 1 hour 8 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 1 hour 8 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 1 hour 26 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 44 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 45 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 10 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 21 hours 48 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 23 hours 23 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 23 hours 23 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 9 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE

News